

Please refer to the accompanying document entitled “Guidance: submitting asset information to the Glo-BNHL Trial Steering Committee”, available to download from the [Glo-BNHL website](#).

## Summary of Asset

Asset Name

Propriety Name

Asset-holder (company)

Asset-holder Contact Name

Asset-holder Contact Email Address

## Regulatory Requirements

Is there an approved Paediatric Investigational Plan for this asset?      No      Yes

Is there an agreed Paediatric Study Plan for this asset?      No      Yes

If yes, please attach the approved document(s)

If no, please describe the current stage of development, including submission timelines

Glo-BNHL shares the formal outcome of asset reviews with regulators.      No      Yes

Do you consent to this?

If no, please describe the reason below

---

## Intellectual Property

Does the named company own the asset? No Yes

Does the named company have the licence to distribute the asset globally? No Yes

If no, please detail below

Are there any other stakeholders of which we should be aware? No Yes

If yes, please detail below

## Development Timelines

Are there any deadlines with regard to this project of which we should be aware? No Yes

If yes, please detail below

---

## Clinical Trial Design

Do you foresee any difficulties with the current protocol in relation to the named asset? (please refer to the Trial Synopsis)

No

Yes

If yes, please detail below

## Statistical Design

Do you anticipate assessment of the names asset requiring any changes to the planned outcome measures? (please refer to the Trial Synopsis)

No

Yes

If yes, please detail below

Please append the additional information detailed in “Guidance: submitting asset information to the Glo-BNHL Trial Steering Committee” and return, with this completed form, to the trial mailbox at [Glo-BNHL@trials.bham.ac.uk](mailto:Glo-BNHL@trials.bham.ac.uk).